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carcinogen, the nitrofuran FANFT (Cohen
et al., 1978). It is not known how saccharin
acts as a promoter, but undoubtedly tumours
promoted by saccharin show a wide variety
of differentiation patterns both within the
tumour and in adjacent, non-neoplastic areas
of the urothelium. This suggests that sac-
charin in some way disturbs the normal
control of differentiation and, like vitamin A
deficiency, encourages random gene trans-
cription, thus increasing the chance of
expression of any neoplastic modification of
the growth-controlling genes introduced by
pre-treatment with an initiator. Saccharin
also causes urothelial hyperplasia in some but
not all animals, and increased numbers ofcells
enter mitosis. Thus saccharin has two
properties characteristic of skin promoters:
it appears to increase the chance of random
transcription of the genome and at the same
time it encourages cell division, thus promot-
ing and propagating tumour growth.
The final result ofneoplastic transformation
in any tissue is an altered phenotype, such
that the cancer cell expresses certain proper-
ties which differ from those of normal cells
from which they were derived. It appears to
be a disease in which some concomitant
phenotypic change in differentiation is obliga-
tory. However, the changes which occur in
a tissue during carcinogenesis may also
illustrate many changes in differentiation
which are not necessarily a part of the neo-
plastic growth syndrome. Promoters encour-
age random gene expression and the produc-
tion of multiple phenotypes, among which
may be the phenotype associated with cancer
growth if the tissue has previously been
exposed to an initiating carcinogen.
This work has been supported over a number of
years by generous grants from the Cancer Research
Campaign.
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PROPERTIES OF SARCOMA GROWTH FACTOR AND OTHER PEPTIDE
HORMONES PRODUCED BY MOUSE AND HUMAN TUMOUR CELLS
G. J. TODARO AND J. E. DE LARCO
From the Laboratory of Viral Carcinogenesis, National Cancer Institute, National Institute of
Health, Bethesda, Md., U.S.A.
MOUSE 3T3 cells have been transformed in
culture by a varietyofagents, includingDNA-
containing viruses (SV40, polyoma), RNA-
containing viruses (e.g. MSV, avian sarcoma
viruses) as well as by various chemical
carcinogens and radiation. Ofthese, the clones
transformed by MSV specifically demonstrate
a loss of cell-surface epidermal growth factor
(EGF) receptors. The basis for this apparent
loss ofreceptors is shown to be the production
by the MSV-transformed cells of a low-mol.-
wt peptide (9-IIK) related to EGF. This
sarcoma growth factor (SGF) stimulates
normal fibroblasts to assume a "transformed"
morphology in monolayer cultures and to
form progressively growing colonies in soft
agar. EGF, under similar conditions, stimu-
lates cell division in monolayer cultures but
not anchorage-independent growth in semi-
solid medium.
SGF has been purified from serum-free
medium of MSV-transformed 3T3 cells. A
critical step in the purification involves the
use of formalin-fixed human carcinoma cells,
designated A431, thathave exceptionally high
levels of EGF receptors (2-2 x 106 receptors/664 BRITISH ASSOCIATION FOR CANCER RESEARCH
cell). The SGF will bind to the receptors at
neutral pH and elute from them in weak acid
with the biological activity (induction of
anchorage-independent growth, stimulation
of cell division, specific binding to EGF
receptors) retained. Cells lacking EGF recep-
tors are unable to respond to either EGF or
SGF. The two growth factors differ from one
another in several ways. Antiserum to EGF
does not immunoprecipitate SGF, and anti-
serum to SGF does not immunoprecipitate
mouse EGF. By isoelectric focusing EGF
has a pI of 4 4, while SGF has a pI of 6-8.
They also migrate differently from oneanother
on polyacrylamide gradient gels. Most impor-
tantly, SGF acts in many ways as a "trans-
forming" protein while EGF does not.
Certain human tumour cells have been
found to produce a peptide growth stimulat-
ing factor that is similar in many respects to
SGF. A factor produced by a human rhabdo-
myosarcoma cell line, A673, has been partially
purified. It has an apparent mol. wt of
21,000 and competes with EGF for EGF-
specific membrane receptors. Like mouse
SGF, it induces normal cells, of either rodent
or primate origin, to proliferate in soft agar,
and it also brings about a rapid morphological
transformation ofcells in monolayers. Binding
to and eluting from the EGF receptor-rich
human carcinoma cells, A431, results in
substantial purification of this growth factor.
The exact relationships between human SGF
and mouse SGF remain to be determined.
The possibility is considered that SGF is a
more"c virulent" form of a normal growth-
regulatory protein.
ECTOPIC HORMONES-AN EPIGENETIC CHANGE EXPRESSED IN
NEOPLASIA?
M. ELLISON
From the Unit of Human Cancer Biology, Ludwig Intitute for Cancer Research, Sutton, Surrey
THE PRODUCTION of a peptide hormone by
a tumour arising in a tissue or organ not
normally associated with that hormone is
now a well established phenomenon in the
biology ofhuman tumours, particularly those
of bronchial origin (Rees & Ratcliffe, 1974).
This apparent phenotypic change accom-
panying the emergence ofa neoplasm presents
an attractive model in which to examine the
relationship between the expression of cell
differentiation and the new acquisition of
specifically neoplastic characteristics.
First it is necessary to establish that a true
heritable change in differentiation has taken
place, not that there is simply a neoplastic
emergence of a small hitherto cryptic popula-
tion of hormone-producing cells. The normal
lung contains populations of cells sharing
ultrastructural (McDowell et al., 1978) and
histochemical (Taylor, 1977) characteristics
with known peptide endocrine cells of the
APUD series, but current evidence has failed
to demonstrate the normal existence of any
of the more commonly tumour-associated
peptide hormones (e.g., ACTH, calcitonin or
vasopressin) in these cells. On the contrary,
tissue-extraction studies have shown a rise in
one ofthese peptides, ACTH, in extracts from
the lungs of a dog subjected to a potentially
carcinogenic stimulus and from a range of
human pathological lung tissues (Yalow,
1979). This suggests that a phenotypic change
can occur in pathological conditions, though
it is not clear which cells of the several types
within the lung are involved.
Evidence on the nature of the hormones
produced by the lung tumours suggests that
they have essentially the same chemical
identity as normal hormones or their pre-
cursors or fragments (e.g., ACTH and related
peptides in a small-cell Ca lung (Bertagna
et al., 1978), although the enzymes respon-
sible for processing the hormones for release
in their "normal" form may be absent or
inappropriate (Lowry et al., 1976). This
suggests that the change which has brought
about the hormone production is an epigenetic
one in which the "normal" gene for the hor-
mone is being expressed in an abnormal or
inappropriate way.
The direct relationship between the pheno-
typic change and the neoplastic initiation is
not yet clear. Evidence from other systems
suggests that carcinogens can effect pheno-